

ABSTRACT OF THE DISCLOSURE

Disclosed are viral variants exhibiting reduced sensitivity to particular agents including nucleoside analogues and immunological mediators such as immunoglobulins and immune
5 cells. Also provided are hepatitis B virus (HBV) variants which exhibit a level of replication fitness in the presence of a nucleoside analogue similar to or greater than in the absence of the nucleoside analogue. The present invention also provides methods of treating HBV infection, including a method for identifying a need to change or otherwise alter an existing therapeutic regimen. Also disclosed are methods for monitoring the development in a subject of an
10 increased HBV load in the presence of a nucleoside analogue. The present invention further provides the use of nucleoside analogue-resistant HBV variants which exhibit a similar or increased replication fitness in the presence of the nucleoside analogue compared to in the absence of the nucleoside analogue to screen for medicaments to treat HBV infection.

4420.000600 2422746